Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic

摘要

Until recently, treatment options for patients with advanced or metastatic cutaneous melanoma were limited. New targeted agents directed against mutant serine/threonine-protein kinase B-raf, including vemurafenib and dabrafenib (GSK-2118436), have shown promising activity in several clinical trials. Rationally designed clinical studies, especially for patients with BRAF-mutant melanoma, have illuminated the complexity of the mitogen-activated protein (MAP) kinase and PI3K/Akt/mTOR signaling pathways. This review focuses on the preclinical and clinical development process of dabrafenib, a selective B-raf inhibitor.